Medication overuse headache (MOH) is a secondary cause of chronic daily headache (CDH) due to the overuse of acute headache medication. All acute treaments can produce MOH with the possible exceptions of DHE and the neuroleptics. MOH was previously called rebound headache, drug-induced headache, and medication-misuse headache. MOH headaches are experienced 15 or more days a month for at least 3 months and have developed or markedly worsened during medication overuse.
1 (Table 1) Overuse is defined in terms of treatment days per month and depends on the drug. Ergotamine-, triptan-or opioid-overuse headache requires intake on 10 or more days a month on a regular basis for 3 or more months, while simple analgesics (or any combination of different acute drugs) require 15 or more days. This translates into 2 to 3 treatment days every week. Evidence suggests that this occurs sooner with triptan than with ergotamine overuse. 2 Medication overuse is often motivated by a patient's desire to treat his headaches or a fear of future headaches.
3 Medication overuse can make headaches refractory to preventive medication.
3
Although stopping the acute medication may result in withdrawal symptoms and a period of increased headache, subsequent headache improvement usually, but not always, occurs.
Patients with MOH can be difficult to treat. Patients should be started on preventive medication (to decrease reliance on acute medication), with the explicit understanding that the drugs may not always become fully effective until medication overuse has been eliminated. 3 Some patients need to have their headache cycle terminated. Outpatient detoxification options, including outpatient infusion in an ambulatory infusion unit, are available. If outpatient treatment proves difficult or is dangerous, hospitalization may be required.
Patients can have severe exacerbations of their migraine during detoxification. Patients often need additional treatment (headache terminators) to break the cycle of CDH and/or help with the exacerbation that occurs when overused medications are discontinued. Withdrawal symptoms include severely exacerbated headaches accompanied by nausea, vomiting, agitation, restlessness, sleep disorder, and (rarely) seizures. Barbiturates, opioids, and benzodiazepines, unless replaced with long-acting derivatives, must be tapered to avoid a serious withdrawal syndrome. 3 Terminaters include repetitive intravenous dihydroergotamine (DHE) which is often coadministered with metoclopramide, which helps control nausea and is an effective antimigraine drug in its own right. The neuroleptics (chlorpromazine, droperidol, haloperidol, and prochlorperazine) are used
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intravenously, intramuscularly, and by suppository, as terminators for nausea, vomiting, and pain. Intravenous ketorolac is a helpful adjunctive treatment. Clinical experience and open label trials suggest that corticosteroids are also effective.
One concern with using neuroleptics is a prolonged QTc interval on EKG. Patients who receive daily repetitive intravenous droperidol should have an EKG before their first dose of the medication and daily thereafter. A QTc that is above 450 msec is considered a 'grey zone' (the drug should be stopped or the dose reduced) and a QTc above 500 msec is a 'red zone' (an absolute contraindication). Bradycardia, abnormal EKG, and a change in the QTc of more than 60 msec are the other risk factors for torsades de pointes associated with prolonged QT syndrome.
